Clinical Trial
A Phase 1/2 Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations
Learn more about this study at
clinicaltrials.gov
For more information contact us here:
Phone
800-600-3606Brief Summary
This is a Phase 1/2 open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Protocol Interventions
Drug: IAM1363, Drug: Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab, Drug: Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + zanidatamab, Drug: Oral treatment with IAM1363 capsules or tablets, administered in combination with T-Dxd, Drug: Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexed
Learn About Clinical Trials
Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.